NO20053776L - Diagnostic imaging agents with MMP inhibitory activity - Google Patents

Diagnostic imaging agents with MMP inhibitory activity

Info

Publication number
NO20053776L
NO20053776L NO20053776A NO20053776A NO20053776L NO 20053776 L NO20053776 L NO 20053776L NO 20053776 A NO20053776 A NO 20053776A NO 20053776 A NO20053776 A NO 20053776A NO 20053776 L NO20053776 L NO 20053776L
Authority
NO
Norway
Prior art keywords
diagnostic imaging
inhibitory activity
imaging agents
pharmaceutical composition
matrix metalloproteinases
Prior art date
Application number
NO20053776A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053776D0 (no
Inventor
Alan Cuthbertson
Anthony Eamon Storey
Marivi Mendizabal
Sally-Anne Ricketts
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Duncan Wynn
Julie Davis
Joseph Arukwe
Kirsty Heywood
Ian Wilson
Bodu Levkau
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302891A external-priority patent/GB0302891D0/en
Priority claimed from GB0307524A external-priority patent/GB0307524D0/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20053776D0 publication Critical patent/NO20053776D0/no
Publication of NO20053776L publication Critical patent/NO20053776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
NO20053776A 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity NO20053776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302891A GB0302891D0 (en) 2003-02-10 2003-02-10 Diagnostic imaging agents for cardiovascular disease
GB0307524A GB0307524D0 (en) 2003-04-01 2003-04-01 Diagnostic imaging agents with MMP inhibitory activity
PCT/GB2004/000524 WO2004069365A1 (en) 2003-02-10 2004-02-10 Diagnostic imaging agents with mmp inhibitory activity

Publications (2)

Publication Number Publication Date
NO20053776D0 NO20053776D0 (no) 2005-08-09
NO20053776L true NO20053776L (no) 2005-09-30

Family

ID=32852413

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053776A NO20053776L (no) 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity

Country Status (8)

Country Link
US (1) US8231858B2 (https=)
EP (1) EP1592458A1 (https=)
JP (1) JP2006519216A (https=)
AU (1) AU2004210208B2 (https=)
CA (1) CA2514885A1 (https=)
NO (1) NO20053776L (https=)
RU (1) RU2005123801A (https=)
WO (1) WO2004069365A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2008045298A2 (en) * 2006-10-06 2008-04-17 Mallinckrodt Inc. Self-aligning radioisotope elution system
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US9153350B2 (en) 2011-01-19 2015-10-06 Mallinckrodt Llc Protective shroud for nuclear pharmacy generators
US8866104B2 (en) 2011-01-19 2014-10-21 Mallinckrodt Llc Radioisotope elution system
US8809804B2 (en) * 2011-01-19 2014-08-19 Mallinckrodt Llc Holder and tool for radioisotope elution system
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
EP2644601A1 (en) * 2012-03-28 2013-10-02 Westfälische Wilhelms-Universität Münster Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren

Also Published As

Publication number Publication date
EP1592458A1 (en) 2005-11-09
WO2004069365A1 (en) 2004-08-19
US8231858B2 (en) 2012-07-31
AU2004210208A1 (en) 2004-08-19
RU2005123801A (ru) 2006-03-27
JP2006519216A (ja) 2006-08-24
WO2004069365A8 (en) 2004-09-30
CA2514885A1 (en) 2004-08-19
US20070071670A1 (en) 2007-03-29
AU2004210208B2 (en) 2007-06-07
NO20053776D0 (no) 2005-08-09

Similar Documents

Publication Publication Date Title
NO20053776L (no) Diagnostic imaging agents with MMP inhibitory activity
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
SV2011003786A (es) Compuestos quimicos 251
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
UY31180A1 (es) Derivados de (1r, 2r)-n-(1-cianociclopropil)-2-ciclohexanocarboxamidas sustituidas, procedimiento de preparación, composiciones faramacéuticas conteniéndolos y aplicaciones.
NO20076053L (no) Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
GB0428250D0 (en) Organic compounds
TW200738698A (en) Organic compounds
WO2006094763A8 (en) 3,4,5-substituted piperidine compounds
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
ATE418540T1 (de) Galloylpeptide
WO2009114136A3 (en) Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
TNSN08287A1 (en) 3,5-substituted piperidine compounds as renin inhibitors
WO2007144129A3 (en) Pyrrolidine derivatives useful against diseases that depends on activity of renin
BRPI0407350A (pt) Combinações farmacêuticas compreendendo corticóides e imunosupressores para tratamento de doenças resistentes aos corticóides e/ou inibidores de calcineurina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application